In a retrospective cohort study, Suzuki et al. [101] examined the risk of developing CVD events among T2DM patients without a history of CVD with newly initiated SGLT2 inhibitor therapy, and they noted no significant differences in the risk of developing MI, stroke, AF, HF and angina pectoris between patients on therapy with empagliflozin, dapagliflozin, canagliflozin or other SGLT2 inhibitors (ipragliflozin, tofogliflozin, luseogliflozin) [101]. The gene discussed is SLC5A2; the disease is hydrops fetalis.